Aaron Seth Kesselheim, M.D.
Co-Author
This page shows the publications co-authored by Aaron Kesselheim and Ameet Sarpatwari.
Connection Strength
25.464
-
Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. JAMA Netw Open. 2022 01 04; 5(1):e2144386.
Score: 0.979
-
Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. Health Aff (Millwood). 2021 05; 40(5):772-778.
Score: 0.934
-
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug Saf. 2021 Jul; 44(7):743-751.
Score: 0.933
-
INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges. J Law Med Ethics. 2021; 49(1):6-9.
Score: 0.913
-
Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Saf. 2021 Mar; 44(3):327-335.
Score: 0.906
-
Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation? BMJ. 2020 10 08; 371:m3841.
Score: 0.898
-
Missed Opportunities on Emergency Remdesivir Use. JAMA. 2020 07 28; 324(4):331-332.
Score: 0.886
-
Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support. Ann Intern Med. 2020 03 03; 172(5):348-350.
Score: 0.856
-
Reforming the Orphan Drug Act for the 21st Century. N Engl J Med. 2019 Jul 11; 381(2):106-108.
Score: 0.824
-
A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. J Gen Intern Med. 2019 03; 34(3):420-428.
Score: 0.796
-
The US Biosimilar Market: Stunted Growth and Possible Reforms. Clin Pharmacol Ther. 2019 01; 105(1):92-100.
Score: 0.794
-
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. JAMA. 2018 06 19; 319(23):2373-2374.
Score: 0.766
-
Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. Health Aff (Millwood). 2018 05; 37(5):732-737.
Score: 0.759
-
Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clin Pharmacol Ther. 2018 06; 103(6):1093-1099.
Score: 0.736
-
Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Drug Saf. 2017 02; 40(2):105-108.
Score: 0.696
-
Factors Influencing Prescription Drug Costs in the United States-Reply. JAMA. 2016 12 13; 316(22):2431-2432.
Score: 0.690
-
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30; 316(8):858-71.
Score: 0.672
-
Navigating the Dermatological Drug Cost Curve. JAMA. 2016 Jun 28; 315(24):2724-5.
Score: 0.668
-
State Initiatives to Control Medication Costs--Can Transparency Legislation Help? N Engl J Med. 2016 Jun 16; 374(24):2301-4.
Score: 0.666
-
Efficacy of the Priority Review Voucher Program. JAMA. 2016 Apr 19; 315(15):1660-1.
Score: 0.659
-
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry? PLoS Med. 2016 Feb; 13(2):e1001955.
Score: 0.650
-
Experience With the Priority Review Voucher Program for Drug Development. JAMA. 2015 Oct 27; 314(16):1687-8.
Score: 0.638
-
The 21st century cures act: Opportunities and challenges. Clin Pharmacol Ther. 2015 Dec; 98(6):575-7.
Score: 0.635
-
Progress and Hurdles for Follow-on Biologics. N Engl J Med. 2015 Jun 18; 372(25):2380-2.
Score: 0.617
-
Expanded access to investigational drugs. N Engl J Med. 2015 04 09; 372(15):1473-4.
Score: 0.614
-
Paying physicians to prescribe generic drugs and follow-on biologics in the United States. PLoS Med. 2015 Mar; 12(3):e1001802.
Score: 0.611
-
Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia. Clin Pharmacol Ther. 2015 Feb; 97(2):186-93.
Score: 0.601
-
Using a drug-safety tool to prevent competition. N Engl J Med. 2014 Apr 17; 370(16):1476-8.
Score: 0.573
-
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. Health Aff (Millwood). 2021 08; 40(8):1198-1205.
Score: 0.238
-
Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Clin Pharmacol Ther. 2021 10; 110(4):1050-1056.
Score: 0.236
-
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States. JAMA Intern Med. 2021 07 01; 181(7):995-997.
Score: 0.236
-
Generic Competition for Drugs Treating Rare Diseases. J Law Med Ethics. 2020 12; 48(4):789-795.
Score: 0.227
-
Clinical Development Times for Biosimilars in the United States. Mayo Clin Proc. 2020 10; 95(10):2152-2154.
Score: 0.224
-
Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clin Pharmacol Ther. 2020 12; 108(6):1308-1314.
Score: 0.222
-
Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists. Am J Manag Care. 2020 08; 26(8):340-347.
Score: 0.222
-
Novelty of Active Ingredients in High-Cost Brand-Name Drugs. J Gen Intern Med. 2020 07; 35(7):2219-2221.
Score: 0.213
-
Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study. Ann Intern Med. 2019 11 05; 171(9):605-611.
Score: 0.209
-
The Impact Of Price Regulation On The Availability Of New Drugs In Germany. Health Aff (Millwood). 2019 07; 38(7):1182-1187.
Score: 0.206
-
Orphan Drug Designation and Exclusivity for "Same Drugs". J Law Med Ethics. 2019 06; 47(2):347-349.
Score: 0.204
-
The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. N Engl J Med. 2018 Sep 20; 379(12):1097-1099.
Score: 0.195
-
Strategies That Delay Market Entry of Generic Drugs. JAMA Intern Med. 2017 11 01; 177(11):1665-1669.
Score: 0.183
-
Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 2017 08 15; 318(7):609-610.
Score: 0.181
-
The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS One. 2017; 12(4):e0175313.
Score: 0.176
-
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Aff (Millwood). 2017 02 01; 36(2):362-370.
Score: 0.174
-
Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. Drug Saf. 2016 08; 39(8):709-14.
Score: 0.168
-
Regulatory Solutions to the Problem of High Generic Drug Costs. Open Forum Infect Dis. 2015 Dec; 2(4):ofv179.
Score: 0.160
-
Forbidden and Permitted Statements about Medications--Loosening the Rules. N Engl J Med. 2015 Sep 03; 373(10):967-73.
Score: 0.158
-
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015 Jan 15; 372(3):279-86.
Score: 0.151
-
Ensuring patient privacy in data sharing for postapproval research. N Engl J Med. 2014 Oct 23; 371(17):1644-9.
Score: 0.149
-
Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany. Health Aff (Millwood). 2020 07; 39(7):1185-1193.
Score: 0.055
-
Correction to: FDA and EMA Biosimilar Approvals. J Gen Intern Med. 2019 Dec 05.
Score: 0.053
-
Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. J Gen Intern Med. 2019 11; 34(11):2339-2341.
Score: 0.053
-
FDA and EMA Biosimilar Approvals. J Gen Intern Med. 2020 06; 35(6):1908-1910.
Score: 0.053
-
Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Med. 2019 03; 16(3):e1002763.
Score: 0.050
-
Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. Drug Saf. 2019 01; 42(1):85-93.
Score: 0.050
-
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ. 2018 Apr 03; 361:k1180.
Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.